Literature DB >> 6836275

Digoxin-inactivating bacteria: identification in human gut flora.

J R Saha, V P Butler, H C Neu, J Lindenbaum.   

Abstract

Digoxin, the most widely used cardiac glycoside, undergoes significant metabolic conversion in many patients to cardioinactive metabolites in which the lactone ring is reduced. This appears to occur within the gastrointestinal tract. An attempt was made to isolate and identify the organisms capable of reducing digoxin from stool cultures obtained from human volunteers. Of hundreds of isolates studied, only Eubacterium lentum, a common anaerobe of the human colonic flora, converted digoxin to reduced derivatives. Such organisms were also isolated in high concentrations from the stools of individuals who did not excrete these metabolites when given digoxin in vivo. When the growth of E. lentum was stimulated by arginine, inactivation of digoxin was inhibited. Neither the presence of these organisms alone nor their concentration within the gut flora appeared to determine whether digoxin would be inactivated by this pathway in vivo.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6836275     DOI: 10.1126/science.6836275

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  67 in total

Review 1.  Challenges Associated with Route of Administration in Neonatal Drug Delivery.

Authors:  Matthew W Linakis; Jessica K Roberts; Anita C Lala; Michael G Spigarelli; Natalie J Medlicott; David M Reith; Robert M Ward; Catherine M T Sherwin
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

Review 2.  Xenobiotics: Interaction with the Intestinal Microflora.

Authors:  Kun Lu; Ridwan Mahbub; James G Fox
Journal:  ILAR J       Date:  2015

Review 3.  Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?

Authors:  Lingeng Lu; Yixing Wu; Lingjun Zuo; Xingguang Luo; Peter J Large
Journal:  World J Microbiol Biotechnol       Date:  2013-10-09       Impact factor: 3.312

4.  Pharmacological Activation of PXR and CAR Downregulates Distinct Bile Acid-Metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis.

Authors:  Joseph L Dempsey; Dongfang Wang; Gunseli Siginir; Qiang Fei; Daniel Raftery; Haiwei Gu; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

5.  Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys.

Authors:  Yang Shen; Yang Yu; Wei Lai; Shuai Li; Zixuan Xu; Jiejing Jin; Xia Yan; Han Xing; Xijing Chen; Aizhen Xiong; Chunhua Xia; Jiake He; Kui Hong
Journal:  Pharm Res       Date:  2018-11-06       Impact factor: 4.200

6.  Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease.

Authors:  Rajkumar Malayandi; Phani Krishna Kondamudi; P K Ruby; Deepika Aggarwal
Journal:  Drug Deliv Transl Res       Date:  2014-04       Impact factor: 4.617

Review 7.  Pharmacokinetic interactions with digoxin.

Authors:  S M Rodin; B F Johnson
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

8.  Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction.

Authors:  Jens Rengelshausen; Christoph Göggelmann; Jürgen Burhenne; Klaus-Dieter Riedel; Jochen Ludwig; Johanna Weiss; Gerd Mikus; Ingeborg Walter-Sack; Walter E Haefeli
Journal:  Br J Clin Pharmacol       Date:  2003-07       Impact factor: 4.335

Review 9.  Developing a metagenomic view of xenobiotic metabolism.

Authors:  Henry J Haiser; Peter J Turnbaugh
Journal:  Pharmacol Res       Date:  2012-08-09       Impact factor: 7.658

Review 10.  The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.

Authors:  Peter Spanogiannopoulos; Elizabeth N Bess; Rachel N Carmody; Peter J Turnbaugh
Journal:  Nat Rev Microbiol       Date:  2016-03-14       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.